Speakers

Expand/Collapse

Adam Lazorchak
Group Leader, Oncology & Immunopharmacology
EMD Serono

Day Two

10:15 am | Bintrafusp alfa, A Bifunctional Fusion Protein Simultaneously Blocking PD-L1 and TGF-ß in Tumor Microenvironment

David Evans
Chief Scientific Officer
Sirnaomics

Day One

12:30 pm | RNAi Therapeutics for Oncology: Silencing TGFb and Cox2 in HCC and NMSC

Paul Rennert
President & Chief Scientific Officer
Aleta Biotherapeutics

Day Two

3:00 pm | Fireside Chat: TGF-ß's Role in the Suppressive Function of T Cells in the TME - Challenges & Opportunities

Olaf Christensen
VP, Head of bintrafusp alfa, Global Development
EMD Serono

Day One

4:30 pm | Chair’s Closing Remarks

10:00 am | Chair's Opening Remarks

Day Two

4:45 pm | Chair’s Closing Remarks

10:00 am | Chair's Opening Remarks

Yan Lan
Senior Director in ImmunoOncology
EMD Serono

Shannon Turley
Senior Director, Cancer Immunology
Genentech

Day One

10:15 am | TGF-β’s Significance in the Cancer Immunotherapy Landscape

Yulei Wang
Principal Scientist, Oncology Biomarker Development
Genentech

Day One

3:30 pm | Clinical Biomarkers to Inform Therapeutic Development of TGF-ß Blockades in Immuno-Oncology

10:45 am | Panel Discussion: Debating the Best Approach to Target TGF-ß

Nadege Bercovici
CR1 – CNRS
Institut Cochin

Day One

4:00 pm | Evaluating TGF-ß Blockers in Combination Therapies: The Challenges of Preclinical Tumor Models

Bruce Rogers
Chief Scientific Officer
Morphic Therapeutic

Day One

1:30 pm | Round Table Discussion: Small Molecule Approach to Inhibiting the Moderation of TGF-ß

James Gulley
Chief, Genitourinary Malignancies Branch Head, Immunotherapy Group, GMB Director, Medical Oncology Service
Center for Cancer Research, NCI, NIH

Day Two

10:45 am | Bintrafusp alfa: It Takes Two To Tango

Julius Strauss
Co-Director Laboratory of Tumor Immunology and Biology
NCI

Viviana Cremasco
Senior Principal Scientist
Novartis

Day Two

1:00 pm | TGFβ-Blockade Uncovers Stromal Plasticity in Tumors by Revealing the Existence of a Novel Subset of Interferon- Licensed Fibr

Marc Pelletier
Translational Immune Oncology
Novartis

Day One

10:45 am | Panel Discussion: Debating the Best Approach to Target TGF-ß

Vuong Trieu
Chairman & CEO
Oncotelic

Day Two

3:45 pm | Antisense Agents in TGF-ß for Immuno-Oncology Drug Development

Christopher Heery
Chief Medical Officer
Precision BioSciences

Day Two

3:00 pm | Fireside Chat: TGF-ß's Role in the Suppressive Function of T Cells in the TME - Challenges & Opportunities

Aaron Martin
Senior Scientist, Cell Therapy Discovery
Precision BioSciences

Day Two

3:00 pm | Fireside Chat: TGF-ß's Role in the Suppressive Function of T Cells in the TME - Challenges & Opportunities

2:30 pm | Inhibition of TGF-ß Signaling in Gene-Edited Allogenic CAR-T Cells

Sharad Sharma
Senior Principal Scientist & Lab Head, Oncology Research
Sanofi

Day Two

12:00 pm | The Anti-TGFβ Neutralizing Antibody, SAR439459, Blocks the Immunosuppressive Effects of TGFβ & Inhibits the Growth of Syngeneic Tumors in Combination with anti-PD1

Thomas Schurpf
Associate Director
Scholar Rock

Day One

10:45 am | Panel Discussion: Debating the Best Approach to Target TGF-ß

Day Two

12:30 pm | Inhibition of TGFβ1 Activation with SRK-181 to Overcome Primary Resistance to Checkpoint Inhibition Therapy

Dori Thomas-Karyat
Chief Executive Officer
Synthis

Day Two

4:15 pm | Development of Immune Cell Targeted TGF-ß Therapies to Restore Tumor Clearance in Cancer Patients

Rick Gregory
Associate Director
Takeda Oncology

Day One

10:45 am | Panel Discussion: Debating the Best Approach to Target TGF-ß

Rosemary Akhurst
Professor
University of California San Francisco

Day One

3:00 pm | Understanding the Mechanisms of Action of TGF-ß Inhibition as Immunotherapy and How Somatic and Germline Genetics Influence Variable Responses Between Individuals

Rik Derynck
Professor - Departments of Cell, Tissue Biology & Anatomy
University of California San Francisco

Day One

10:45 am | Panel Discussion: Debating the Best Approach to Target TGF-ß

Sam Shrivastava
Chairman & CEO
Venn Therapeutics

Day One

1:00 pm | Integrin αvβ8-Expressing Tumor Cells Serve as a Platform for TGF-ß Activation